Background: Rotavirus vaccination has reduced diarrhoeal morbidity and mortality globally. The
Introduction
Globally, rotavirus mortality in children <5 years was estimated at 527 000 (465 000 -591 000) in 2000 and reduced to 215 000 (197 000 -233 000) in 2013 with more than half of the latter occurring in subSaharan Africa [1] . Two rotavirus vaccines (Rotarix, GlaxoSmithKline Biologicals and RotaTeq, Merck & Co) have been shown to be both safe and effective [2] . The delivery of rotavirus vaccines to children in sub-Saharan Africa should, therefore, provide an important tool in the fight against diarrhoeal diseases [3] .
The icosahedral rotavirus particle has outer capsid proteins, VP7 and VP4, that are able to independently elicit an immune response and were important epitopes during vaccine development [4] . These proteins specify the G and P genotypes, respectively, and to date 35 G and 50 P genotypes have been described [5, 6] . In human infections, five globally predominant (G1, G2, G3, G4 and G9), one recently emerged (G12) and one regionally predominant (G8) G types circulate while two globally predominant (P [8] and P [4] ) and one regionally predominant (P [6] ) P genotypes are detected [7, 8] .
In South Africa (SA) between 2003 and 2005, a prospective burden of disease study investigated children <5 years presenting to the Dr George Mukhari Hospital (DGM) for the treatment of diarrhoea.
The study estimated that rotavirus was responsible for 17 644 -25 630 hospitalizations in children <2 years of age annually [9] . The study also examined rotavirus genotypes prior to vaccine introduction [10] . The dominant rotavirus genotype varied year on year (G2P [4] in 2003, G1P [8] /G1P [6] in 2004, G3P [8] /G3P [6] in 2005 and G1P [8] in 2006) and a variety of unusual genotypes and G/P combinations were detected [10] .
In August 2009, the rotavirus vaccine was introduced into the South African public immunization programme. Preliminary impact analysis estimated that rotavirus vaccine introduction reduced rotavirus hospitalizations by 54-58% in 2010 and 2011 in children <5 years [11] . Further, a case control study from SA demonstrated rotavirus vaccine effectiveness against rotavirus diarrhoea hospitalization of 57% (95% CI 40-68) for two doses [12] .
After the introduction of the monovalent rotavirus vaccine in Mexico and Brazil, reports of increases in the proportion of rotavirus genotypes not present in the vaccine formulation emerged raising concern around replacement disease due to non-vaccine genotypes [13, 14] . In Malawi, post-monovalent vaccine introduction surveillance found higher vaccine effectiveness against fully or partially homotypic rotavirus strains, with lower estimates for heterotypic strains [15] . In Botswana, G2P [4] predominated after monovalent vaccine introduction with G2P [4] vaccine effectiveness of 59% [16] . However, subsequent analyses showed similar vaccine effectiveness against homotypic and heterotypic strains and, lack of dominance of any one rotavirus strain post-vaccine introduction [17] .
Nevertheless, recent modelling utilizing genotype-specific hospitalization data from Belgium pre-and post-vaccine introduction, predicted that G1P [8] strains would be eliminated while G2P [4] strains would persist, which was suggested to be driven by differences in homotypic versus heterotypic immunity of second infections [18] . To date, there is limited characterisation of rotavirus genotypes post-vaccine introduction from African countries and continued surveillance is required to elucidate what effect (if any) rotavirus vaccination has on circulating rotavirus strains in resource poor settings.
The aim of this study was to evaluate the rotavirus genotype distribution before 
Materials and Methods
Hospital-based rotavirus surveillance in children <5 years presenting with acute diarrhoea has been conducted at DGM since early 1980s [19] . Data on rotavirus detection and genotype distribution from years, who were admitted to a sentinel hospital for the treatment of acute diarrhoea (WHO definition; seven days or less), were approached for enrolment. Enrolment was conducted systematically from Monday to Friday (8am-5pm) and demographic, clinical and outcome data were collected in a structured questionnaire by dedicated surveillance officers from consenting parents/guardians. Stool specimens were collected for rotavirus screening.
Laboratory procedures
All specimens from DGM were tested at the MRC-DPRU. Between 2002 and 2008, stool specimens were screened using the IDEIA™ Rotavirus kit (DAKO Ltd., Cambridgeshire, UK) [10, 20] Rotavirus positive samples detected using enzyme immunoassays were further characterized to determine the G and P genotype. The dsRNA was extracted from the stool using TRI-Reagent LS (Molecular Research Centre, Cincinnati, OH) or the QIAamp Viral RNA Mini kit (Qiagen, Hilden, Germany) and genotyped using standardized RT-PCR methods and primers for G-specific (G1, G2, G3, G4, G8, G9, G10, G12) and P-specific (P [4] , P [6] , P [8] , P [9] , P [10] , P [11] , P [14] ) genotypes [21] . Where the genotyping methods produced inconclusive results, VP7 and VP4 genes were amplified and Using 2009 as the baseline year, the odds ratio and significance (p≤0.05) of rotavirus detection at all sentinel sites (including DGM) were calculated using multivariable logistic regression analysis and a model adjusted for site and age. Rotavirus genotypes were compared by year and site using the Royston chi-square test for trend. In addition, selected genotype (G1, P [8] and non-G1P [8] ) prevalence from the expanded surveillance sites was evaluated by year with Wilson confidence intervals calculated for binomial proportions. Genotype prevalence (G1, P [8] and non-G1P [8] ) was evaluated for two time periods (2010-2011 and 2012-2014) with odds ratios and significance (p≤0.05) calculated using multivariable logistic regression in a model adjusted for site and age. All analysis was implemented using STATA 14.1 (StataCorp LP, College Station TX).
Results

Temporal changes in rotavirus prevalence and genotype distribution pre-and post-vaccine introduction at Dr George Mukhari Hospital
Between January 2002 and December 2014, 6870 stool specimens from DGM were screened with 23% (95% confidence interval (95% CI) 20-25; 1588/6870) positive for rotavirus ( Table 1 (Table 1) . Nevertheless, there was a decline in the proportion of G1 strains over the post-vaccine period (p for trend <0.001). A similar decreasing trend was not noted for P [8] strains at DGM (p for trend = 0.11). Conversely, there was an increase in the proportion of non-G1P [8] genotypes over time (p for trend <0.001; Table 1 ). However, non-G1P [8] strain percentage fluctuated greatly over the study period, varying from 17-76% pre-vaccine and 14-92% post-vaccine introduction (Table 1) . (Table 3; Supplementary Table 2 ). While G1P [8] G2P [4] G2P [6] G12P [8] G9P [8] G1P [8] surveillance (G1P [8] , G2P [4] and G12P [8] ; p for trend < 0.001; Table 3 ). In 2014, two genotypes circulated with G1P [8] strains predominant in 3 of 5 sites (39-44%) and G2P [4] predominant in 2 of 5 geographically diverse sites (42-75%; p for trend <0.001). In years where uncommon rotavirus strains (G12P [8] in 2011) circulated, the diversity of genotypes seemed to diminish (Table 3 ). Genotype G12P [8] 
Temporal changes in rotavirus genotype
Discussion
The current study suggests that the monovalent rotavirus vaccine introduction into the national immunization program was temporally associated with changes in genotype circulation in SA. The decrease in G1 strains was similar at DGM, a site with genotyping data from 2002, as well as geographically diverse sentinel sites, using 2009 as a baseline. In Malawi, G1P [8] prevalence showed a non-significant decline of 54% post-vaccine introduction compared to the pre-vaccine era [15] . In Morocco, G1P [8] strains were not detected the third year after vaccine introduction [22] . These results seem to support in part the model predicted by Pitzer and colleagues that G1P [8] would decline [18] .
However, reviews of genotypes after vaccine introduction have shown that efficacy in developing countries is diminished against both heterotypic and homotypic rotaviruses [17] . In SA, G1P [8] strains re-emerged in 2014 and were responsible for 29% of rotavirus cases. These results suggest that while Evaluation of G1P [8] strains before and after monovalent rotavirus vaccine introduction in Belgium showed a reduction in the proportion of strains within the vaccine strain cluster [23] . In addition, a novel double-gene reassortant with G1 and P [8] genes on a DS-1 backbone was detected in Japan,
Thailand and Vietnam [24, 25, 26] . The re-emergence of G1P [8] strains in SA requires additional attention to determine whether natural strain fluctuation or gene reassortment contributed to the increased circulation in 2014. The G1P [8] strains did not persist in 2015 and were replaced by G9P [8] and G3P [4] rotaviruses in 2016 [27] .
Increased rotavirus cases were noted in 2013 despite universal rotavirus vaccination being available. In the US, a biennial increase in rotavirus has been seen but "high" seasons remained below pre-vaccine levels [28] . One explanation for the larger season in 2013 as well as the re-emergence of G1P [8] strains in 2014 may be due to low rotavirus vaccine coverage in 2013; officially reported at 89% by the South African National Department of Health and estimated by WHO and UNICEF at 64% [29] . An alternative explanation could be an increase in rotavirus-specific antibodies in women who had children after the large rotavirus season in 2013. High levels of transplacental rotavirus antibodies have been shown to reduce vaccine seroconversion [30] . Children receiving rotavirus vaccine in 2014 may have had lower vaccine seroconversion due to maternal antibodies thereby allowing the temporary re-emergence of G1P [8] strains. (p<0.001). These results highlight a study limitation as only one site had rotavirus genotyping data for more than one year before vaccine introduction. In addition, genotype varied between sentinel sites so that data from one site may not be generalizable to the rest of the country. Genotype variation in different geographic sites in one country is not uncommon and was seen in SA before vaccine introduction [19] and in Morocco after vaccine introduction [22] .
In addition to a decrease in G1, the study showed an increase in the proportion of non-G1P [8] at levels between 32-86% [31] . However, whether the emergence of G2P [4] in South America was linked to natural fluctuations in rotavirus genotype distribution or the introduction of the monovalent rotavirus vaccine is unknown [14, 31, 32] .
Unlike South America, G2s are relatively common in SA and re-emerge every few years [33] . Between 2003-2010, G2P [4] strains were responsible for 12% of infections at DGM [20] . While G2P [4] strains may have caused a greater proportion of rotavirus cases in 2013, these strains have not persisted.
Fluctuations of other rotavirus genotypes (G12P [8] and G9P [8] ) have also been seen in SA. Similarly, analyses of global genotype distribution showed that these strains do not persist [8, 17] . This study has several limitations that should be considered. Rotavirus strains from DGM were partially 
